Loading stock data…
SGRY
$14.26+0.06 (+0.42%)
Pre-Market$15.00+0.74 (+5.19%)· Last close May 5
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Surgery Partners, Inc. in the Healthcare sector is trading at $14.26. The stock is currently 41% below its 52-week high of $24.18, remaining 18.9% below its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why SGRY maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.26
Potential Upside
5%
Whystock Fair Value$14.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$18.68+31.0%
Range$14.00 – $25.00
Fundamentals
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency su...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.91B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-4.55%
Volume
Today's trading volume
2.75M
Recent News
Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates
Surgery Partners (SGRY) delivered earnings and revenue surprises of +80.00% and +1.52%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners’s (NASDAQ:SGRY) Q1 CY2026 Sales Beat Estimates
Healthcare company Surgery Partners (NASDAQ:SGRY) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 4.5% year on year to $810.9 million. The company expects the full year’s revenue to be around $3.4 billion, close to analysts’ estimates. Its non-GAAP loss of $0.03 per share was 77.8% above analysts’ consensus estimates.
Surgery Partners (SGRY) Reports Q1: Everything You Need To Know Ahead Of Earnings
Healthcare company Surgery Partners (NASDAQ:SGRY) will be announcing earnings results this Tuesday before the bell. Here’s what to expect.
Surgery Partners Inc. (SGRY): Billionaire Brian Higgins Likes This Stock
We just covered Billionaire Brian Higgins’ 10 Stock Picks With Huge Upside Potential and Surgery Partners, Inc. (NASDAQ:SGRY) ranks 4th on this list. Surgery Partners, Inc. (NASDAQ:SGRY) is a long-term holding in the 13F portfolio of King Street Capital. The fund first disclosed a stake in the company back in the third quarter of 2019. […]
1 Mooning Stock with Impressive Fundamentals and 2 We Ignore
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.